XNASTARS
Market cap2.01bUSD
Jan 10, Last price
52.69USD
1D
-4.62%
1Q
47.55%
IPO
139.50%
Name
Tarsus Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
115.45
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
46.97%
Rev. gr., 5y
%
Revenues
17m
-32.42%
Net income
-136m
L+118.86%
CFO
-117m
L+139.63%
Earnings
Feb 25, 2025
Profile
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 17,447 -32.42% | 25,816 -54.73% | ||||
Cost of revenue | 51,905 | 88,528 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (34,458) | (62,712) | ||||
NOPBT Margin | ||||||
Operating Taxes | (4) | |||||
Tax Rate | ||||||
NOPAT | (34,458) | (62,708) | ||||
Net income | (135,893) 118.86% | (62,091) 349.06% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 118,599 | 74,352 | ||||
BB yield | -19.93% | -20.60% | ||||
| Debt | ||||||
Debt current | 398 | 721 | ||||
Long-term debt | 32,849 | 20,207 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 233 | 100 | ||||
Net debt | (194,826) | (196,469) | ||||
| Cash flow | ||||||
Cash from operating activities | (117,493) | (49,030) | ||||
CAPEX | (1,502) | (506) | ||||
Cash from investing activities | 140,604 | (144,629) | ||||
Cash from financing activities | 130,176 | 93,987 | ||||
FCF | (36,274) | (62,411) | ||||
| Balance | ||||||
Cash | 227,442 | 217,026 | ||||
Long term investments | 631 | 371 | ||||
Excess cash | 227,201 | 216,106 | ||||
Stockholders' equity | (244,653) | (108,832) | ||||
Invested Capital | 473,606 | 321,973 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 29,383 | 24,620 | ||||
Price | 20.25 38.13% | 14.66 -34.84% | ||||
Market cap | 595,011 64.86% | 360,925 -21.96% | ||||
EV | 400,185 | 164,456 | ||||
EBITDA | (33,581) | (62,387) | ||||
EV/EBITDA | ||||||
Interest | 3,346 | 2,199 | ||||
Interest/NOPBT | ||||||